** ASX-listed shares of Aroa Biosurgery rise as much as 15.4% to A$0.6, their highest since Aug. 12
** NZ's Medical products maker expects to be operating cash flow positive in the second half of FY25
** Co says FY25 normalised EBITDA guidance maintained at NZ$2 mln ($1.21 mln) to NZ$6 mln
** Says, FY25 revenue guidance maintained between NZ$80 mln and NZ$87 mln
** ARX to release financial results for H1 FY25 on Nov. 26
** Stock down 30.7% YTD
($1 = 1.6543 New Zealand dollars)
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。